Lunai Bioworks Licenses Tanaist Technology for Parkinson's Research Platform

Lunai Bioworks, Inc. (LNAI) announced on September 23, 2026, a worldwide license and collaboration agreement with Tanaist, Inc. to integrate human cellular phenotyping into its Parkinson's disease discovery and validation platform. The AI-driven drug discovery company said the deal expands its platform's capabilities by adding human cell-based analysis to its existing research tools. Financial terms of the agreement were not disclosed. Lunai Bioworks uses artificial intelligence to identify and validate potential drug candidates. The company did not provide a timeline for when the Tanaist technology would be incorporated into its Parkinson's research pipeline.